Research
Hormonal
Tirzepatide (5-15 mg weekly) results in significant mean weight loss (15.0-20.9%) and improvements in waist circumference, blood pressure, and lipid levels compared to placebo.
Tirzepatide, taken as a weekly injection at doses of 5, 10, or 15 mg, can lead to 15-21% weight loss over 72 weeks, along with improvements in blood pressure and lipids, compared to placebo.
StrongSupportsHIGH confidence
In an RCT, adults who received tirzepatide lost a mean weight of 15.0%, 19.5% and 20.9% at doses of 5 mg, 10 mg or 15 mg, respectively, compared with 3.1% with placebo; waist circumference, blood pressure and lipid levels also decreased over 72 weeks.
Why this rating
Based on a cited RCT (SURMOUNT-1).
Source
Novel obesity treatments
Shohinee Sarma et al. · Canadian Medical Association Journal · 2023
narrative_reviewCited 1×
Read the paper This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →